Watch These Novo Nordisk Stock Price Levels After Last Week's 33% Drop

Novo Nordisk's U.S.-listed shares are experiencing a modest rebound after a significant one-third decline last week, which was triggered by a cut in full-year guidance, the appointment of a new CEO, and subsequent analyst downgrades. This sharp sell-off, extending a broader two-thirds value loss since June last year, is attributed to intensifying competition from Eli Lilly and setbacks in the company's next-generation obesity drug trials. Technical analysis indicates strong selling conviction, with investors closely watching key support levels at $36 and $29, and resistance at $60 and $78.

Analysis

Novo Nordisk (NVO) is facing significant fundamental and technical headwinds, despite a minor 2% rebound in recent trading. The stock shed approximately one-third of its value last week, driven by a confluence of negative catalysts including a reduced full-year outlook, the appointment of a new CEO, and subsequent Wall Street downgrades. This sharp decline extends a much larger downtrend, with shares having lost about two-thirds of their value since their peak in June of last year, pressured by intensifying competition from Eli Lilly's (LLY) weight-loss drugs and setbacks in its own next-generation obesity drug trials. The technical picture is decidedly bearish; last week's sell-off occurred on above-average volume, indicating strong selling conviction from institutional investors. Furthermore, the potential formation of a 'death cross'—where the 50-week moving average crosses below the 200-week moving average—signals the likelihood of lower prices ahead. While the Relative Strength Index (RSI) is nearing oversold territory, which could precipitate short-term bounces, key support levels are now established at approximately $36 and $29, with significant overhead resistance anticipated near $60 and $78.

Key Decisions for Investors

• Given the negative fundamental catalysts and bearish technical signals, including a potential 'death cross', investors should exercise caution as the stock's path of least resistance appears to be downward.
• Traders should closely monitor the critical support levels around $36 and $29, as a sustained break below these areas could trigger another wave of selling, while any recovery will face its first major test at the $60 resistance level.
• The competitive pressure from Eli Lilly is a core component of the bearish thesis, and any further market share gains by LLY in the weight-loss segment will likely continue to weigh heavily on Novo Nordisk's valuation.
• While the near-oversold RSI may offer opportunities for short-term tactical bounces, these should be viewed with skepticism until the stock can reclaim significant technical levels and demonstrate a change in the negative fundamental narrative.